Endoprotease 40 (E40)
an adjunct aid to gluten digestion, enzymatically detoxifying gluten proteins in both the stomach and intestine, reducing gluten exposure and related symptomatology
an adjunct aid to gluten digestion, enzymatically detoxifying gluten proteins in both the stomach and intestine, reducing gluten exposure and related symptomatology
E40 is a novel acidic serine-carboxyl peptidase of the S53 family, recombinantly expressed and secreted in its functional form by our proprietary Streptomyces lividans engineered strains during industrial fermentation.
As a single enzyme, E40 retains proteolytic activity between pH 2.5 and 7, enabling its dual sites of action – in the stomach and small intestine – and its contiguous protection in functional gastrointestinal ailments such as accelerated gastric emptying and/or slow intestinal transit, common in CeD.
E40 completely detoxifies α-gliadin derived peptides within gastrointestinal digesta, with no detectable traces of the 33-mer and 25-mer, and only traces of ω- and γ-gliadin GIPs.
Preventing GIP generation by degrading immunodominant peptide sequences in advance of any direct pharmacological and immunological interaction with tTG2 and HLA-DQ2.5 and DQ8 competent cells in the lamina propria of the small intestine, E40 significantly reduces interferon-γ response in CeD derived intestinal T-cell lines exposed to E40-treated gluten digesta.
E40 presents with a NOAEL of 640mg/kg body weight/day and has been shown to be safe and effective in preclinical gluten challenge studies. No systemic absorption of E40 has been observed.
E40 is well positioned to be the first fully effective, safe and readily available preventative solution for symptomatic gluten exposure.
Commercial launch throughout the EU is expected in 2028, upon completion of E40 clinical evaluation, and subsequent approval for market authorisation.
Strain engineering (Completed)
E40 is expressed and secreted in its active form by our proprietary Streptomyces lividans TK24, Red 1.3 engineered strains (WO2023285135).
Fermentation parameters (Completed)
Fermentation parameters are optimised to maximise the secreted active E40 in the fermentation broth from stable, repeatable fermentation runs.
Down Stream Production (‘DSP’) parameters (Completed)
Downstream purification parameters are optimised, yielding high purity E40 active substance form, formulated with a common excipient to yield a stable finished powder form.
Industrial scale manufacturing (Completed)
The fermentation and DSP steps have been sequentially scaled up with lab scale indications translating directly to industrial scale manufacture.
Manufacturing validation (Completed)
GMP manufacturing process validation batches have been successfully completed at industrial scale.
QA / QC documentation (Completed)
The fully compliant, industrial scale GMP manufacturing process is defined and active, yielding GMP certified formulated powder.
Market ready GMP commercial form (In progress)
Granulation and encapsulation studies are ongoing finalisation for the production of capsules to be used in the clinical evaluation, fully representing the final commercial product.
Commercial launch ready
The GMP manufacturing process is established and produces E40 formulated powder in the final commercial product form with no further studies required for launch, following successful completion of the clinical evaluation.
LLNA (Completed)
A skin sensitization assay demonstrated E40 protein does not induce allergenicity. Further, the absence of any skin irritation classifies E40 as Class I product, being safe for workers involved in commercial manufacturing and distribution.
28 day toxicology study – 1st species (Completed)
E40 successfully completed a 28-day, repeated dose toxicity study in Wistar rats, demonstrating a NOAEL of 640mg/kg b.w./day, corresponding to a human equivalent dose of 103 mg/kg b.w./day.
14 day toxicology study – 2nd species (Completed)
E40 successfully completed a 14-day, repeated dose toxicity study in Goettingen pigs, demonstrating a NOAEL of 90 mg/kg b.w./day, corresponding to a human equivalent dose of 75mg/kg b.w./day).
90 day toxicology study – 2nd species (In progress)
A 90-day, repeated dose toxicity study in Goettingen pigs is scheduled to be completed in Q127.
Commercial launch ready
Robust safety and tolerability support continued progression to clinical evaluation.
INFOGEST (Completed)
In human simulated digestion of bread, pasta and beer, as per the harmonized INFOGEST protocol, E40 demonstrated a dose-dependent degradation of c.95% whole gluten contained in the examined food matrices.
None of Immunodominant α-gliadin peptides were detected in E40-treated digesta.
Suppressed T-cell activation (Completed)
Strongly reduced or absent interferon-γ responses occurred in human celiac intestinal T-cell lines derived from bioptic samples, when exposed to E40-treated gluten digesta.
Traces of ω- and γ-gliadin derived immunogenic peptides detected in E40-treated digesta were unable to stimulate ex-vivo IFN-γ responses.
HLA DQ8 gliadin challenge (Completed)
HLA-DQ8 mice, a recognized model of gluten sensitivity mimicking some features of CeD upon gluten intake, were gluten challenged. E40 confirmed in vivo its extensive gliadin detoxification.
No 33-mer and 25-mer were detected in E40 treated gastric digesta. Suppressed T-cell line stimulation was observed.
A partial – although significant – recovery from villous blunting was detected in E40 treated HLA-DQ8 enteropathic mice.
Gluten challenge in animal model (Completed)
Yorkshire pigs on a GFD – a most appropriate model for human digestion – were gluten challenged with 8g gluten (mimicking a Western diet).
E40 was confirmed to detoxify GIPs in GI and urine samples.
The complete data set for this US DoD PRMRP study will be received in Q42026.
Phase 1/2 clinical investigation (Planned)
A single definitive clinical investigation is planned as the final step to complete the safety and performance portfolio, supporting market authorization (as a Medical Device) throughout the EU, to be undertaken across specialist CeD centres recruiting a total of c.100 participants and expected to conclude in H128.
Commercial launch ready
E40 has consistently demonstrated its high activity in detoxifying GIPs at each stage of the performance pathway and we are excited to conclude this portfolio through the completion of our upcoming, comprehensive clinical evaluation.
Confirmation of Medical Device classification (Completed)
E40 is proposed to be classified as a Medical Device under EU regulations (EU2017/745), following its risk assessment by a qualified Notified Body (‘NB’). This regulatory approach provides for an accelerated path to market whilst ensuring E40 continues to clearly demonstrate its safety and performance for its intended use.
Preparation of dossier (In progress)
Preparation of the dossier to be submitted to the NB is well under way, documenting the significant existing body of evidence on E40’s development, including CMC, toxicology and pre-clinical evidence to date, with the successful clinical evaluation outputs to be included in due course.
Submission to Notified Body (Planned)
Once clinical data is available, the dossier will be submitted to the NB for E40 qualification as a Medical Device throughout Europe.
Market Authorisation throughout EU (Planned)
Award of E40’s CE mark, demonstrating its European Conformity with health, safety and environmental protection standards and authorising its commercial sale throughout the EEA, supporting its 50+m citizens currently following a GFD to avoid symptomatic gluten exposure.
Manufacture of commercial launch volumes (Planned)
Concurrent with the submission of the dossier to the NB, commercial manufacturing will scale up to prepare product volumes for commercial launch on award of the CE mark.
Commercial launch
With the existing ability to manufacture the commercial product, at industrial scale and with the high level of confidence in relation to the safety and performance of E40, commercial launch is timed to follow award of the CE mark, with distribution partners having already entered into option agreements for a number of territories.
Whilst the current focus is on achieving first commercial launch (throughout Europe), driving cash generation, and:
work continues to progress medium term milestones including:
E40 is protected by a growing portfolio of patents and know how as well as various finished product trademarks
Proprietary production strains – Recombinant Streptomyces lividans strains have been deposited under the Budapest Treaty at the Leibniz Institute DSMZ, supporting the protection of E40 manufacturing technology for 30 years
WO 2013/083338 – E40 enzyme discovery – protects Actinoallomurus-derived gluten degrading enzymes, including E40, their sequences and applications.
WO 2021/013553 A1 – E40 manufacturing process – Covers recombinant E40 production in Streptomyces lividans, including optimized fermentation and enzyme recovery processes.
WO 2023/285135 A1 – Advanced E40 expression systems – protects engineered Streptomyces lividans production strains and chromosomally integrated expression systems for high-yield E40 manufacturing.
Nemysis Limited had reserved the worldwide trademark ‘Nomer’, reflecting the complete detoxification of the 33-mer (No …. mer) and providing a global brand opportunity.
E40’s development has been subject to the scrutiny and support of leading grant programs

US Department of DefensePeer Reviewed Medical Research Program
HT94252410750 – The development of an oral enzymatic therapy adjunctive to the dietary management of celiac disease.
ENTERALIA BIOSCIENCE LLC | USA spending
Funding provided by the US Department of Defense is supporting a gluten challenge study in Yorkshire pigs, a 14-day toxicology study and a 90-day toxicology study in Goettingen pigs.
Enteralia Bioscience LLC is a wholly owned subsidiary of Nemysis Limited

European UnionHorizon Accelerator Program
190138713 – First ever preventive treatment for celiac disease and gluten sensitivity
EU Funding & Tenders Portal 190138713
Funding provided under the EU Horizon programme supported the pre-clinical development of E40 as well as establishing its industrial manufacturing process.
E40 is materially derisked, representing a compelling investment case for co-development and commercialisation of a critical solution to a highly prevalent unmet need
Nemysis Limited welcome conversations with potential partners to support the final steps to market authorisation and commercialisation of E40, to share the full potential of this key product.
We welcome any enquiries and would be happy to speak to participants at ICDS 2026